(MedPage Today) -- Alirocumab clear of problems seen with bococizumab, researchers say
via PCSK9 Antidrug Antibodies: Not a Class Effect
by
Showing posts with label PCSK9 Antidrug Antibodies: Not a Class Effect. Show all posts
Showing posts with label PCSK9 Antidrug Antibodies: Not a Class Effect. Show all posts
Saturday, March 18, 2017
Subscribe to:
Posts (Atom)